MedPath

University of Manitoba

University of Manitoba logo
🇨🇦Canada
Ownership
Private
Established
1877-02-28
Employees
5K
Market Cap
-
Website
http://www.umanitoba.ca

Clinical Trials

537

Active:20
Completed:269

Trial Phases

6 Phases

Early Phase 1:5
Phase 1:23
Phase 2:35
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (458 trials with phase data)• Click on a phase to view related trials

Not Applicable
348 (76.0%)
Phase 2
35 (7.6%)
Phase 4
25 (5.5%)
Phase 1
23 (5.0%)
Phase 3
22 (4.8%)
Early Phase 1
5 (1.1%)

Perioperative Virtual Reality Intervention for Pain and Anxiety During Vasectomies

Not Applicable
Not yet recruiting
Conditions
Vasectomy
Pain
Anxiety
Virtual Reality
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
University of Manitoba
Target Recruit Count
90
Registration Number
NCT07055178
Locations
🇨🇦

Manitoba Men's Health Clinic, Winnipeg, Manitoba, Canada

Advancing Family Wellbeing Through a Massive Open Online Intervention: The LightBEAM Program

Not Applicable
Recruiting
Conditions
Anger
Parenting
Depression, Anxiety
Stress Psychological
Parent Child Relationship
Child Development
First Posted Date
2025-06-18
Last Posted Date
2025-06-18
Lead Sponsor
University of Manitoba
Target Recruit Count
300
Registration Number
NCT07026838
Locations
🇨🇦

University of Manitoba, Winnipeg, Manitoba, Canada

CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children

Phase 2
Not yet recruiting
Conditions
Drug Resistant Epilepsy
Interventions
Drug: Placebo
Drug: CBD CHE
First Posted Date
2025-06-17
Last Posted Date
2025-06-17
Lead Sponsor
University of Manitoba
Target Recruit Count
90
Registration Number
NCT07023744

Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period

Phase 3
Not yet recruiting
Conditions
Benign Prostate Hypertrophy(BPH)
Interventions
Drug: Beta-3 agonists (Mirabegron/Myrbetriq)
Other: Placebo group post rezum
First Posted Date
2025-06-12
Last Posted Date
2025-06-12
Lead Sponsor
University of Manitoba
Target Recruit Count
50
Registration Number
NCT07017439
Locations
🇨🇦

Men's Health Clinic Manitoba, Winnipeg, Manitoba, Canada

Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia

Phase 3
Not yet recruiting
Conditions
Benign Prostate Hypertrophy(BPH)
Interventions
First Posted Date
2025-06-12
Last Posted Date
2025-06-12
Lead Sponsor
University of Manitoba
Target Recruit Count
48
Registration Number
NCT07017452
Locations
🇨🇦

Men's Health Clinic Manitoba, Winnipeg, Manitoba, Canada

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 108
  • Next

News

Theralase's Ruvidar® Shows Complete Healing of HSV-1 Lesions in Preclinical Study

Theralase's topical Ruvidar® treatment demonstrated complete healing of HSV-1 cutaneous lesions in mice after four days of application, marking a significant breakthrough in herpes treatment.

Risk Stratification and Population Health Key to Revolutionizing CKD Care Management

Advanced risk stratification models are enabling precise identification of high-risk CKD patients and connecting them with appropriate therapies, bridging the gap between diagnostics and treatment.

© Copyright 2025. All Rights Reserved by MedPath